A phase II trial of an anti-HER3 monoclonal antibody, CDX-3379, and cetuximab in a population of heavily pretreated patients with head and neck squamous cell carcinoma (HNSCC) demonstrated antitumor activity with an acceptable safety profile [147]. The gene discussed is ERBB3; the disease is head and neck squamous cell carcinoma.